Le Lézard
Classified in: Health
Subjects: MAV, PDT, CFG

/R E P E A T -- NOTICE TO THE MEDIA - Minister of Health to make an announcement related to An Act Respecting Pharmacare/


OTTAWA, ON, Feb. 28, 2024 /CNW/ - The Honourable Mark Holland, Minister of Health, will make an announcement related to An Act Respecting Pharmacare.

There will be a virtual media technical briefing with Government of Canada officials prior to the press conference.

Date
February 29, 2024

Time

Media technical briefing: 10:30 AM (EST)
Press conference: 11:30 AM (EST)

Location

Virtual media technical briefing:
The technical briefing will be held on Zoom and will be for background information only (not for attribution). Participation in the question and answer portion of the technical briefing is for accredited members of the Press Gallery only. Media who are not members of the Press Gallery may contact [email protected] for temporary access.

A teleconference line is also available for listening to the event:

Toll-free dial-in number (Canada/US):
1-866-206-0153

Local dial-in number:
613-954-9003
Participant passcode: 7836876#

Press conference:
Centertown Community Health Centre
420 Cooper Street 
Ottawa, Ontario 

Media may also join by Zoom:
https://hc-sc-gc-ca.zoom.us/j/67043624587
Passcode: 560883

NOTE: To help ensure optimal simultaneous interpretation sound quality, journalists are encouraged to use a microphone (headphones/headset) or, when possible, a landline, and to avoid using speaker mode if queuing up for questions.

Twitter: @GovCanHealth
Facebook: Healthy Canadians

SOURCE Health Canada (HC)


These press releases may also interest you

at 08:40
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract about its Phase 2 THIO-101 clinical trial named "A phase 2, multicenter,...

at 08:35
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today reported its...

at 08:32
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
Moleculin Biotech, Inc., ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its abstract has been accepted for poster...

at 08:32
VitalTalk Training Emphasizes Compassionate Conversations For Enhanced Clinical Interactions
In a complex medical environment, seriously ill patients and family members need support navigating the healthcare system and deciding on the best courses of treatment. VitalTalk was developed to ensure that every patient is cared for by clinicians...

at 08:30
Assure Announces Approval of Increase in Authorized Capital at Adjourned Special Shareholders Meeting
Assure Holdings Corp. (the "Company" or "Assure") , a provider of intraoperative neuromonitoring ("IONM") and remote neurology services, announced today that at its adjourned Special Shareholder Meeting held on May 14, 2024, shareholders approved the...

at 08:30
FastWave Medical Granted Fifth Utility Patent Reflecting Continuous Expansion of IVL IP Portfolio
FastWave Medical, a clinical-stage medical device company developing advanced intravascular lithotripsy (IVL) technology, achieves a significant milestone with the issuance of its fifth utility patent by the United States Patent and Trademark Office...

More news about Health...


News published on and distributed by: